Mar 11 |
Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
|
Feb 26 |
Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
|
Feb 8 |
Cadrenal Therapeutics appoints Jeff Cole as COO
|
Feb 8 |
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
|
Jan 31 |
Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
|
Jan 30 |
Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation
|
Jan 24 |
Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
|
Jan 20 |
Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO
|
Jan 18 |
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|